EGFR and non-small cell lung carcinoma: While secondary EGFR mutations are a well-characterized mechanism of acquired resistance to EGFR inhibition in EGFR-mutated NSCLC, de novo co-occurring EGFR alterations that modulate sensitivity to TKIs have only rarely been described18–20.